Donate

There are really two pandemics currently wreaking havoc across the US. Both involve the same COVID-19 virus, but while they are both terrifying and dangerous, they differ in the type of damage they are causing. One epidemic is a general contagion afflicting everyone. Even...
As coronavirus infections in the US soar past the 150,000 mark, making the US epicenter a growing world-wide COVID-19 pandemic that has shut down the US economy and threatens a global recession, the Pentagon, seemingly on autopilot, continues to focus its spending on such purported national security...
Across the country, expanding the dental workforce to include dental therapists is one of a very few health care proposals that attracts support from lawmakers in both parties.
There is clear evidence the pharmaceutical industry manipulates well-intentioned laws to increase prices and profits. We’ll use two laws as our case studies, the Orphan Drug Act of 1983 and the Hatch-Waxman Act of 1984 which jumpstarted the generic drug industry. The first was designed to give incentives to drug...
How health insurance cash forms opinions on Medicare for All.
I’ve been thinking a lot about health-care mergers and acquisitions lately, and I must confess, it’s making me dizzy. All of this head-spinning thought was prompted primarily by the creation of Ballad Health Care, now the sole hospital system for my entire region of the country. Ballad was established about...
The current network of health cares and doctors has prevented people with uncommon conditions and smaller hometowns to lose critical options, Trudy Lieberman writes.
This analysis was written by Tarbell board member Diane Archer and originally published in the health news and advisory platform Just Care on 3/6/2019. Tarbell is republishing this piece with permission. 
If ever there were a weak link in hospital care, it's what happens when you or a loved one leaves the hospital. It's becoming clear that the process known as discharge planning is deficient, can be harmful, and sometimes results in a patient's decline. One in five patients across the...
David Lichtenstein A new treatment could extend David’s life by 33%. But he can’t afford to take it. David Lichtenstein has ALS, also known as Lou Gehrig’s disease, and likely has only 3 to 5 years to live. This summer, the FDA approved a new treatment called Redicava that could extend...
Department of Health and Human Services Secretary nominee Alex Azar would be the first former drug industry executive to lead the agency if he is confirmed by the Senate. A Tarbell review of past HHS secretaries – and before that leaders of its predecessor bureau, the Department of Health Education and Welfare...
The Democratic debates may make you think Americans are scared of "losing" private insurance. But candidates who Medicare For All are still going strong.
The Senate Special Committee on Aging has just released one of the most damning reports on the nation’s nursing homes that I’ve seen in a long time. The short document should be required reading for any family thinking of moving a relative to a nursing facility. Pennsylvania Senator Robert Casey,...
Congress has prohibited the government from bargaining for cheaper Medicare medications under Part D.
Is the beloved program on its last legs?
You have no guarantee that the doctors and hospitals that the insurance company say are in your network will still be there in the future. And you, not the insurer, get stuck with a the big bill. 
Researchers at Brown and Columbia Universities found that disenrollment from MA plans “may indicate that plans do not meet the preferences of enrollees with significant chronic illness.”
My former colleagues undoubtedly where cheering when they heard Sen. Michael Bennet (D-Colo.) come to the defense of private health insurers and trash the idea of improving and expanding Medicare to cover all Americans.
The pharmaceutical industry doesn’t just contribute to patient groups or the lawmakers themselves through campaign contributions to assert influence. It floods the U.S. Capitol with lobbyists. A Tarbell analysis of lobbying disclosures found that the leading drugmakers that make up the Pharmaceutical Research and Manufacturers Association, and the association itself, have spent...
Consumers hoping a couple of recent policy proposals might lower prices for their prescription drugs may be out of luck, at least for now.  Earlier this year, the Trump administration had proposed a rule that would have required prescription drug manufacturers to disclose list prices for drugs advertised on TV. ...